EP0232262A1 - Microorganisme producteur de tryptophane - Google Patents

Microorganisme producteur de tryptophane

Info

Publication number
EP0232262A1
EP0232262A1 EP85904319A EP85904319A EP0232262A1 EP 0232262 A1 EP0232262 A1 EP 0232262A1 EP 85904319 A EP85904319 A EP 85904319A EP 85904319 A EP85904319 A EP 85904319A EP 0232262 A1 EP0232262 A1 EP 0232262A1
Authority
EP
European Patent Office
Prior art keywords
tryptophan
host
plasmid
control
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85904319A
Other languages
German (de)
English (en)
Other versions
EP0232262A4 (fr
Inventor
Desmond Mascarenhas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stauffer Chemical Co
Original Assignee
Stauffer Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stauffer Chemical Co filed Critical Stauffer Chemical Co
Publication of EP0232262A1 publication Critical patent/EP0232262A1/fr
Publication of EP0232262A4 publication Critical patent/EP0232262A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • C12P13/227—Tryptophan

Definitions

  • the present invention relates to Escherichia coli (E. coli) microorganisns carrying plasmid borne genetic information for the prcduction of L-tryptophan and methods for prcducing and increasing the fermentative production of L-tryptophan.
  • Escherichia coli E. coli
  • Tryptophan is an amino acid that is an essential component in animal nutrition. Its fermentative production by microorganisns from inexpensive carbohydrate substrates is highly desirable.
  • Microorganisms used to this end include Brevibacterium (U.S. Pat. 3,700,539), Enterobacter (U.S. Pat. 4,439,627), Bacillus, particularly Bacillus subtilis [using anthranilate and carbon, nitrogen and mineral sources (U.S. Pat. 4,363,875; Japanese Patent Application J58017190, 1,3-5A, and European Patent Application EP 81-107)] and Corynebacterium glutamicum ATCC 21851.
  • E. coli strains described therein carry a specific plasmid having thereon genes of the wild type tryptophan operon ( trpA-E ) with a wild type or temperature sensitive tryptophan repressor gene (trpR or trpRts, respectively) for control of tryptophan biosynthesis.
  • trpA-E wild type tryptophan operon
  • trpR or trpRts wild type or temperature sensitive tryptophan repressor gene
  • Such plasmid or multicopy plasmid may also carry a Serine B gene (SerB).
  • the present invention is intended to meet the persistent need for inexpensively produced tryptophan by providing a bacterial host microorganism, of the genus Escherichia, deficient in the enzyme tryptophanase carrying plaanid borne information for the production of tryptophan wherein said information is divided between at least two plaanids.
  • Another object of the invention is to provide a method for producing tryptophan by culturing the above-mentioned bacterial host and plaanids therein in a culture medium and recovering L-tryptophan from the fermented culture medium.
  • Still another object of the invention is to provide inexpensively produced tryptophan by providing a bacterial host microorganian of the genus Escherichia deficient in the enzyme tryptophanase carrying plaanid borne genetic information for the prcduction of tryptophan wherein a portion of said information for the production of tryptophan is under lac operator/promoter control.
  • Yet another object of the invention is to provide a method for producing tryptophan by culturing the above-mentioned bacterial host with plaanid borne information for the prcduction of tryptophan, a portion of said information being under lac operator/promoter control in a culture medium and recovering tryptophan from the fermented culture median.
  • a still further object of the invention is to increase the production of tryptophan by a bacterial host of the genus Escherichia deficient in the enzyme tryptophanase by transforming said host with plasmid borne information to control tryptophan production divided between at least two plaanids; or by transforming the bacterial host as described with plaanid borne information to control tryptophan production a portion of said information being under lac promoter/operator control, or by transforming said host as described with plasmid borne information to control tryptophan prcduction divided between at least two plaanids, a portion of said information to control tryptophan prcduction being under lac operator/promoter control.
  • the plaanids used in this invention may be E. coli plaanids or plaanids capable of replicating in E. coli. If the information to control tryptophan prcduction is distributed on more than one plasmid, it is desirable to use plaanids that are replication compatible. Thus, for example, when the information to control tryptophan prcduction is distributed on two plaanids, plaanids having a ColE1 origin of replication may be used to carry part of the information and plaanids having a p15A origin of replication may be used to carry another part of the information.
  • Useful in the plasmid constructions of the type described in the invention are the following: ColEl, pSC101, pSF2124, pMB3, pMB9, pACYC184, pACYC177, pCK1, R6X, pBR312, pBR313, pBR317, OBR318, pBR320, PSR321, pBR322, pBR333, pBR341, pBR345, pBR350, pBR351, pML2, pML21, ColElaD, RSF1010, pVH51, pVh151, pVH153 (Recombinant Molecules: Impact on Science and Society: Beers, R.F., and Bassett, E.G., eds.
  • the preferred plasmids are the multicopy plaanids of the type of pBR and its derivatives, ColEl and its derivatives, p15A and its derivatives, pHH509 and its derivatives and pSC101 and its derivatives.
  • At least one of the plaanids may furthermore be desirable for at least one of the plaanids to contain a par locus (Meacock, P.A. and Cohen, S.N., Cell, 20:529-542 (1980)). If the information to control tryptophan production is distributed anong more than two plaanids it is preferred that all plaanids be replication compatible with each other, by constructing them such that they each carry different origins of replication.
  • the plaanids used in the invention are single copy (stringent) or multicopy (relaxed) plasmids. Because tryptophan yields can be increased by increasing the copy nunber of plaanids carrying information multicopy plaanids are preferred. Although multicopy plaanids can be frequently lost from the host cell, i.e., are unstable, plasmid copy nunber may be maintained by constructing the plasmids such that determinants of antibiotic resistance are carried thereon. By adding antibiotics to the culture medium, microorganisms that lose plasmids are eliminated or fall to insignificant nunbers, depending on the mode of antibiotic action.
  • Plasmids used in this invention bear genetic information to control tryptophan production.
  • the term "information to control tryptophan production" according to the invention includes:
  • the controlling elements used in the invention are nucleotide sequences derived from the lactose operon and include the lac operon promoter/ operator and lac repressor sequences. According to the invention, various portions of 1 and 2 are under lac control and produce significant amounts of functional gene products only in the presence of lactose. According to the invention it is preferred that tandem lac operator/promoters are used to achieve greater levels of gene expression than are possible with a single lac promoter.
  • the genetic information to control tryptophan prcduction according to the invention comprises a large n ⁇ nber of DNA sequences ceding for genes and regulatory sequences thereof, which are plaanid borne.
  • the terms "gene” or “genes” as used herein are meant to encompass a DNA sequence ceding for an active product of the gene.
  • DNA sequences ceding for an active gene product are genes within this definition even though the particular DNA sequence may not include the complete structural gene for the active product of the gene.
  • the genetic information to control tryptophan production on plaanids it is convenient to divide the genetic information between at least two plasmids.
  • the elenents can be positioned relative to information they control and their gene products can be produced in sufficient concentration to insure that the information controlling biosynthesis of the common aromatic amino acid precursors, information controlling biosynthesis of tryptophan from chorismic acid and/or information controlling biosynthesis of serine are expressed under optimum conditions and at the desired time in a fermentation cycle.
  • the plaanid-borne information to control tryptophan prcduction is divided between at least two plasmids.
  • Figure 1 and Figure 2 are schematic drawings of the preferred embediments of the plaanids carrying information to control tryptophan production according to the invention.
  • Fragment Numbers 1-11 of Table 1 read in conjunction with Figure 1 identifying each restriction endonuclease segment of each plaanid.
  • Fragment Numbers 12-14 identify the restriction endonuclease segments of the plaanid within Figure 2.
  • Table 1 further identifies each segment by approximate size in kilobases (kb), restriction nuclease ends of each fragment, genes/loci on the fragment, sequence coordinates if known, and journal reference for each known sequence coordinate.
  • the depicted segment sizes in Figure 1 are only approximately proportional to the size of the complete plaanid as shown.
  • coli host strains may be transformed by growing them to an optical density of about 0.6 at 600 nanometers in liquid median, chilling the cell suspension on ice for approximately 5 minutes, harvesting the cells by centrifugation, washing the cells in chilled 10 mM MgCl2, harvesting the cells, resuspending in chilled 50 mM CaCl 2 for about 30 minutes and adding plaanid DNA in suspension and maintaining the mixture at 0°C for about 45 minutes; the cells are resuspended in growth median for about one hour at 37 °C. Transformed host cells are selected or screened on appropriate medium.
  • the ⁇ 1059 Sau3A E. coli genomic DNA clone bank was constructed by ligating Sau3A partial digests of E. coli genomic DNA to BamHI-cleaved ⁇ 1059 arms, thus generating a bank of recombinant phage containing randan pieces of the entire E. coli genome.
  • the general methods for generating such a ⁇ 1059 Sau3A E. coli genomic DNA clone bank are well known to those skilled in the art. Clone banks using other vectors and restriction endonuclease digests are also known.
  • Plaanids are generally isolated from host cells by the Birnboim cesium chloride gradient method. (Birnboim, H.C., Doly, J., Nucleic Acids Research, 7:1513-1523 (1979).) After restriction endonuclease digestion, plaanid fractions are generally fractionated by electrophoresis on an agarose or acrylamide gel, with appropriate molecular weight standards, using a buffer of 4 mM Tris, 1 mM EDTA adjusted to pH 8.2. Fragments are subsequently washed in ethanol and resuspended in Tris EDTA buffer at pH 8.0.
  • T 4 ligase Ligation of restriction endonuclease-cut DNA fragments is generally carried out with T 4 ligase in 50 mM Tris-HCl (pH 7.8), 10 mM MgCl 2 , 20 mM dithiothreitol, 1 mM ATP and 50 ug/ml bovine serum albunin.
  • T 4 ligase may be used to catalyze the formation of phosphcdiester bonds between juxtaposed 5' phosphate and 3'-hydroxyl termini in double-stranded DNA. Both blunt and cohesive end restriction fragments may be ligated using T 4 ligase.
  • Unpaired terminal bases of restriction endonuclease cut DNA fragments are made blunt-ended with DNA polymerase I (Poll) in the presence of deoxyribonucleotides (dNTP's).
  • DNA polymerase I Polymerase I
  • dNTP's deoxyribonucleotides
  • approximately 1 micro ⁇ gram (ug) of the purified DNA fragment having unpaired terminal bases is incubated with 2 units of Klenow DNA Polymerase I (Jacobsen et al., Eur. J.
  • Media for antibiotic selection or screening of plasmid containing microorganians is formulated to sustain growth of the microorganian of interest theredn, but contains, unless otherwise indicated, 20 mg/l of the antibiotic of interest.
  • Media used in the construction of the host strains and plasmid described hereinbelow are as follows: LB per liter tryptone 10 grans (g) yeast extract 5 g sodium chloride 5 g glucose 2 g
  • Difcc ® yeast extract 5 g scdiun chloride 10 g glucose 2 g chlortetracycline 50 milligrams (mg)
  • Plates ( solid medium) are made by adding agar ( 1 .5%) .
  • Plasmid pD2643 comprising trpA-E genes of which trpA-D are under lac promoter control, lacking a trp attenuator region, carrying a tetracycline resistance gene ( tet r ) and having a ColEl-type origin of replication was constructed as follows.
  • Tandem lac promoters were removed from pKB252 ( lac PUV5) (K.
  • pCM126 was partially digested with Bglll and completely digested with SaIl restriction endonucleases.
  • a Sall-EcoRI fragment containing a gene for anthranilate synthetase resistant to feed-back inhibition by tryptophan was obtained as follows. An EcoRI digest of Serratia marcescens gencmic DNA was prepared, and fr ⁇ n an agarose gel a 4-9 kb fraction thereof was isolated. Said 4-9 kb fraction was ligated into EcoRI-digested pACYC184 under conditions favoring formation of hybrid molecules, and the resultant plaanid was used to transform E. coli strain M717 (D. Helsinki) deleted for trpE. Colonies were selected that grow on minimal medium. Plaanid pC501 carrying trpC-E was isolated from one of the selected colonies.
  • Plasmid-linked 7-methyltryptophan (7 MT) resistance was selected by treating a strain carrying pC501 with ethyl methane sulfonate and selecting for resistant mutants on minimal medium containing 7MT and tetracycline.
  • One such mutant had a plasmid gene (trpE) ceding for an anthranilate synthetase resistant to inhibition by tryptophan.
  • a 1.6 kb Sall-EcoRI fragment of the mutant derivative of pC501, having an altered trpE gene encoding an anthranilate synthetase resistant to inhibition by tryptophan was ligated into Sall-PstI digested pCM136.
  • An EcoRI-PstI fragment of pBR327 containing a tet r gene was added to this ligation mixture.
  • Plaanid pD2643 was constructed by deleting Amp r activity from pD2623 by digestion with Ahalll restriction endonuclease, ligation with the T 4 ligase, transformation of an E. coli host microorganism to Tet r and screening for ampicillin sensitivity.
  • Plasmid pD2625 Plaanid pD2625 coding for aroG activity which is feedback resistant to inhibition by aromatic amino acids (under lac control), serA and lacl activity, a par locus and a p15A origin of replication was constructed in the manner described immediately below.
  • a nucleotide sequence ( ⁇ 1059 serA) derived from an E. coli K12 genomic clone bank (Karn et al., Proc. Nat'l. Acad. Sci., 77, 9:5172-5176 (1980); clone bank obtained from M. Benedik, Stanford University) was isolated, digested with Ncol restriction endonuclease and ligated into Ncoldigested pACYC184 under conditions favoring formation of hybrid molecules.
  • E. coli serine auxotroph JC158 (A.J. Clark via B. Bachmann) was transformed to Tet r and serine independence using aliquots of the hybrid molecules.
  • pD2528 was isolated from a serine independent Tet r transformant of JC158.
  • pD2528 DNA was digested with EcoRI and SaIl and was ligated using T 4 ligase into EcoRI-Sall digested pBR327 under conditions favorable for plaanid formation.
  • pD2537 was isolated from transformants of E. coli (JC158) that were Amp r , Tet s and Ser + .
  • a bacteriophage carrying the genes of the lac operon was obtained from the ⁇ 1059-E. coli genomic bank indicated above. Lac activity was identified by complenentation of a Lac- E. coli strain (B1361) carrying plaanid pDE4081 (Mascarenhas et al. Virology, 26:658-668 (1983)) on lactose minimal plates. The ⁇ 1059 lac phage thus selected was digested with Bglll. A 10.5 kb Bglll fragment obtained from this digest was ligated to BamHI-digested pACYC184 and the hybrid was used to transform B1361 to Cam r Lac + .
  • This 1 .35 kb Narl fragment was ligated into pACYC184 digested with Clal restriction endonuclease-forming plaanid pD2333 having lacI activity, Cam r and a P15A origin from plasmid pACYC184.
  • a SaIl restriction site located between an Aval and BamHI site on plasmid pD2333 was eliminated by digestion with Aval followed by addition of Klenow Pol I, dNTP ' s, BamHI linkers and T 4 ligase. This was followed by digestion with BanHI and re-circularization of the resulting large fragment with T 4 ligase, to form pD2348.
  • Plasmid pD2348 was digested with restriction endonucleases Nrul and SaIl. The digest was combined with a 1 . 1 kb EcoRI- SaIl fragment of pEM31 containing a partition (par) locus (Meacock and Cohen, Cell , 20: 529542 (1980 ) ) , and T 4 ligase, Klenow Poll and dNTP ' s. The resulting plasmid pD2349 which is Cam r and has a P15A origin of replication, par locus and lacl activity was isolated by screening for Cam r transformants.
  • Plasmid pC520 was digested with Bglll and BanHI restriction endonucleases, and a 1.6 kb Bglll-BamHI fragment from this digest was ligated into Bglll- BamHI digested plasmid pCM126 using T4 ligase to form pD2149, a plaanid in which aroG activity is under tandem lac promoter transcriptional control.
  • pD2149 was digested with PstI to form PstI fragments. These fragments were ligated to a BamHI adaptor sequence which converts the PstI fragments ends to BamHI ends. From the converted BamHI fragments, a 2.8 kb BamHI fragment carrying the aroG gene under tandem lac promoter control was isolated by gel electrophoresis and was ligated using T 4 ligase into BanHI digested pD2349 to form pD2351 which is characterized as follows: Cam r , p15A origin, par locus, lacl activity, tandem lac promoters linked to aroG.
  • a 2-nucleotide shift in the arcG locus of pD2351 was introduced by Clal restriction endonuclease digestion in the presence of Klenow Poll and dNTP's, followed by treatment with T4 ligase.
  • the frane shift renders pD2351 incapable of expressing DAHP synthetase, the peptide product of aroG, yet conserves practically the whole arcG nucleotide sequence.
  • the plaanid with the frane shift is used to transform E. coli strain MAR13 (Held and Smith, J.
  • Gal r Tet r derivative of NK6969 (Roberts, D.) and carries a complete deletion of the aroG gene.
  • Colonies are selected for growth on minimal medium containing nicotinanide, chloramphenicol, tyrosine and tryptophan. Colonies that grow under these conditions are screened individually by enzyme assay [Doy and Brown, Bicchanica et Biophvsica. Acta., 104:377389 (1965)] to identify those which contain a feedback resistant DAHP synthetase (arcG fbr ) activity. The plaanid in one such isolate was designated pD2422.
  • Plasmid PD2434 in which the arcG fbr activity is brought under lac operator control is constructed from pD2422 as follows: a sample of plasmid pD2422 is digested with Bglll restriction endonuclease, Klenow Pol I and dNTP's to form an 8.5 kb fragment having blunt ends. The 8.5 kb ⁇ lunt-ended fragment is digested with Xhol restriction endonuclease to form a 7.4 kb fragment having one blunt end and one Xhol end.
  • Another sample of pD2422 is digested with Ddel restriction endonuclease and Klenow Pol I with dNTP's to form multiple fragments with blunt ends. These blunt ended Ddel fragments are then digested with Xhol restriction endonuclease to form a 1.0 kb fragment having an Xhol end and a blunt end. The 7.4 kb and 1.0 kb fragments are purified, mixed and ligated using T 4 ligase, to form plaanid pD2434.
  • Plasmid pD2625 was constructed from pD2434 and pD2537 in the following manner.
  • pD2537 was digested with Clal and Nrul restriction endonuclease to yield a 1.85 kb fragment having a Clal end and a blunt end.
  • a sample of pD2434 was digested with Clal and Bglll restriction endonuclease to yield a 7.7 kb fragment with a Bglll site adjacent to and downstream of the lac promoter and a Clal site in the arcGfbr gene.
  • a second sample of pD2434 was digested with XmnI and BallI restriction endonuclease to yield a 1.4 kb fragment having an XmnI end and a Bglll end.
  • the 7.7 kb fragment of pD2434, 1.85 kb fragment of pD2537 and 1.4 kb fragment of pD2434 were ligated together with T 4 ligase and were used to transform JC158 (J.C. Clark via B. Bachmann) to Cam r Ser + .
  • One of these transformants yielded plaanid pD2625.
  • a plasmid pD2624 in which the serA fragment is inserted into pD2434 in the opposite reading sense from that of pD2625 was also constructed by digesting a sample of pD2434 with Xhol and Bglll to yield a 7.4 kb fragment having Xhol and Bglll ends, and digesting a second sample of pD2434 with Xhol and Bglll as before.
  • Plasmid pD2537 was digested with SaIl and MstI to yield a 2.0 kb fragment with a Sall end and MstI blunt end. The fragments were ligated together with T4 ligase as above.
  • the SaIl end of the serA-containing fragment from pD2537 and Xhol end of the large pD2434 fragment are compatible as these two endonucleases produce compatible cohesive termini.
  • Plaanid pGM3207 (shown in Figure 2) carrying serB and serC was constructed in the manner described immediately below in Sections A-C.
  • E. coli serine auxotroph was constructed by transducing strain CGSC #5409 (argI61, argF58, serB28, purA54, thr-25, tonA49, relAl, spoT1; obtained from B. Bachmann) to PurA + with P1 phage grown on strain W3110.
  • One Pur + transductant was purified and designated G3004.
  • a nucleotide sequence ⁇ 1059 serB) derived from an E. coli K12 genomic clone bank (Karn et al., Proc. Nat' 1. Acad. Sci., 77, 9: 5172-5176 (1980); clone bank obtained from M.
  • Eenedik, Stanford University was isolated, digested with BanHI restriction endonuclease and ligated into BamHI-digested pB3339 under conditions favoring the formation of hybrid molecules.
  • E. coli serine auxotroph G3004 was then transformed to Kan r and serine independence using aliquots of the hybrid molecules.
  • Plasmid pGM3147 was isolated as a serine independent Kan r , tet s transformant of G3004.
  • Plasmid pGM3134 was digested with Bglll and Xhol restriction endonucleases, to yield a 5.3 kb Bglll-Xhol fragment containing serC.
  • a sanple of plaanid pGM3147 was digested with Bglll and Sall restriction endonucleases to yield a 9.9 kb Bglll-Sall fragment containing serB and a gene specifying kanamycin resistance.
  • the pGM3134 5.3 kb Bglll-Xhol fragment was ligated to the pGM31479.9 kb Bglll-Sall fragment with T 4 ligase.
  • the products of this ligation mixture were used to transform CGSC #4297 (serC auxotroph) to Kan r , Ser + .
  • Plaanid DNA purified from one of these transformants was used to transform G3004 (CGSC #5409 derivative and serB auxotroph, see above in Section A) to Kan r , Ser + .
  • the transforming plaanid was designated pGM3207.
  • A103 was transduced to tetracycline resistance with a P1 lysate of E. coli strain TST 1 (T.J. Silhavy via B. Bachmann).
  • TST 1 is known to carry a Tn10 insertion in the malE gene (malE52:Tn10) which is closely linked to the gene ceding for phosphoglucose isomerase (pgi).
  • Tet r colonies were selected on LB agar median with 10 mg/l tetracycline and one of these was designated A103T.
  • a nunber of spontaneously-occurring fusaric acid resistant derivatives of A103T were isolated on fusaric acid plates.
  • Fusaric acid resistant isolates were screened on glucose tetrazolion plates and those isolates which formed white colonies on this medium were tested further. One of these was found to be auxotrophic for lysine in the presence of methionine and threonine. Since the genes lysC and malE flank the pgi gene it was assumed that the lysine auxotroph had a complete deletion of the pgi locus. This isolate was designated CT10 and was assumed to be ( lysC-pgi-malE) ⁇ .
  • C534, a Tna- derivative of A103 was constructed in a manner analogous to that described above for C536.
  • Strain D2316 a strain deficient in the prcduction of phenylalanine caused by a deficiency in the pheA gene which cedes for the first enzyme of the phenylalanine biosynthetic pathway, was made by conjugation of strain C536 and strain KA197 (H. Qkestra via B. Bachmann). D2316 was selected as a Trp + phenylalanine auxotrophic transconjugant by replica plating on median either containing or lacking phenylalanine.
  • Strain D2139 was made by P1 transduction of strain MV17 (D. Helsinki, supra) with lysates of MB82 (Benedik et al. Virology, 126:658668 (1983)).
  • Strain D2316 was made Tet r by P1 transduction with lysates of strain D2139, which contains a Tn10 insertion in the trpB gene (trpB::Tn10).
  • a Tet r Trp- transductant was isolated and designated D2317.
  • D2317 was PI transduced to 3-fluorotyrosine resistance with lysates of D2307 described above.
  • D2318 characterized as tryptophan independent, 3-fluorotyrosine resistant and phenylalanine-requiring was one of the transductants obtained.
  • D2318 was P1 transduced using lysates of strain AT2471 (A.L. Taylor via B. bachmann), a tyrA mutant strain. Phenylalanine-independent colonies were selected by growth on median containing tryosine but lacking phenylalanine. Phenylalanine-independent colonies were screened for tyrosine dependence and a Phe + Tyr- strain was isolated and designated D2320.
  • a strain having feedback resistant anthranilate synthetase was constructed from strain D2320 by first making D2320 Tet r by P1 transduction with lysates of D2319.
  • the trpB::Tn10 sequence was introduced into D2320 in a manner analogous to that used in making D2317.
  • One Tet r transductant (D2324) was P1-transduced using lysates of a spontaneously occurring derivative of W3110 having anthranilate synthetase resistant to feedback inhibition by tryptoph.an.
  • a tryptophan independent, 7-methyltrypto ⁇ hanresistant transductant that was auxotrophic for tyrosine and sensitive to tetracycline was selected and designated D2325.
  • Enzyme assays (according to Ito and Crawford, Genetics, 52: 1303-1316 (1965)) in the presence of 2 mM L-tryptophan confirmed that D2325 specified a feedback-resistant anthranilate synthetase.
  • a strain designated D2327 which is auxotropic for phenylalanine and tyrosine independent was made by P1 transduction of D2325 to Tyr + using lysates of strain KA197. (Hoekstra via B. Bachmann).
  • Strain D2327 was made Tet r by P1 transduction with lysates of an E. coli strain (C541) having a Tn10 insertion in the nadA locus and an adjacent deletion removing nadA, aroG, gal. C541 was made by P1 transduction of MV17 (D. Helsinki, supra) with lysates of strain C531. The Tet r derivative of D2327 was then transduced using P1 lysates of strain MAR13 (Held and Smith, supra). Marl 3 carries an arcmatic anino acid feedback resistant DAHP synthetase activity. Transduced cells were isolated as Nad + , Phe-, tetracycline sensitive strains.
  • D2346 In one transductant, feedback resistance of DAHP synthetase to phenylalanine was determined by enzyme assay in the presence of 1 mM phenylalanine. This strain was designated D2346.
  • a phenylalanine independent strain of D2346 was made by P1 transduction of D2346 using lysates of AT2471 (A.L. Taylor, supra) and selecting for phenylalanine independence on median containing tyrosine.
  • One Phe + Tyr- transductant was designated D2402.
  • B1364 is a trp + lac + transductant of B1363 (Mascarenhas et al., Virology, 124:100-108, (1983)) using P1 lysates of W3110.
  • B1364 thus has genetic information for ⁇ -galactosidase, lactose transacetylase, and lactose permease activity all fused to and under the control of the tryptophan operon ( ⁇ trp-lac W205).
  • Strain D2402 was made Tet r by P1 transduction using a lysate of D2139 as above; a Tet r derivative of D2402 was then transduced to Trp + ac + with P1 lysates of strain B1364.
  • Trp + Lac + Tet s 7-methyl-tryptophan resistant (7MT r ) isolate was designated D2432.
  • D2432 was made Tet r by P1 transduction using P1 lysates of strain RS162 (J. Wechsler via B. Bachnann) .
  • the resulting Tet r strain (D2548) has a Tn10 insertion in the zjb locus and a temperature sensitive mutation dnaB252.
  • a spontaneous isolate of this strain capable of utilizing hydroxyphenyl pyruvate was isolated and designated D2549.
  • D2549 was P1-transduced using lysates of strain EG30 (D, Gelfand via B. Bachmann), a strain lacking transaninase A (tyrB-).
  • Transductants were isolated by growth on LB agar at 42°C (loss of dnaB252 mutation) and screened for inability to grow on plates containing p-hydroxyphenylpyruvate.
  • One such isolate was designated D2550.
  • a spontaneous tetracycline sensitive (fusaric acid resistant) derivative of D2550 designated D2618 was selected on fusaric acid plates. D2618 was then made Tet r by P1 transduction using lysates of NK6024 (N. Kleckner via B. Bachmann), a strain having a Tn10 insertion in the pheA locus. Tetracycline resistant colonies were selected and one Phe-Tyr- transductant was designated D2636. Spontaneous fusaric acid resistant (Tet s ) derivatives of D2636 were selected on fusaric acid plates and checked for phenylalanine and tyrosine requirements. One such isolate (Phe-Tyr-Tet s ) was designated D2637.
  • D2637 was transduced to Tet r (Ser-) using P1 lysates of strain 123A1, which contain a Tn10 insertion linked to the serC locus in strain strain KL282 (K. B. Low via B. Bachmann).
  • One Tet r Ser- transductant, designated D2638 was transduced to Ser + with P1 lysates from DG30 (D. Gelfand via B. Bachmann) which contains an aspC mutation and is auxotrophic for aspartic acid. These transductants were screened for aspartic acid auxotrophy.
  • One aspartic acid auxotroph that was serine independent and Tet S was designated D2639.
  • Serine deaninase-deficient derivatives of D2637 were constructed as follows: Strain MEW191 and a P1-sensitive derivative of strain 1K15-5 (both strains received from E. Newman, Concordia University) are believed to carry mudX ( Cam,Amp) insertions in regulatory and structural genes for L-serine deaminase, respectively. A P1 lysate of each of these strains was used to transduce D2637 to Cam r Mp r . Single transductants from each cross were designated D2711 and D2713 respectively, and were deemed to carry the mudX (Cam, Mp) insertions (regulatory:D2711, structural:D2713) present in their respective parents.
  • mudX Cam,Amp
  • D2714 and D2715 were isolated and designated D2714 and D2715 respectively. Enzyme assays confirmed that both D2714 and D2715 were deficient in L-serine deaminase activity.
  • C534 and C536 are isogenic E. coli strains except that the pgi gene has been deleted in C536.
  • C534 was made by PI transduction of A103 using lysates grown on C537 and screening for Tna- colonies.
  • C536 was described above. These strains were cured of their resident plasmids by isolation of Amp s segregants in each case. These cured derivatives were then transduced to Tet R with P 1 grown on D2636 (tyrA4 pheA18: :Tn10 ) .
  • D2704 Single transductants were then cured of the transposon by selection of spontaneous fusaric-acid-resistant segregants on fusaric acid plates.
  • D2704 was Pgi + Tyr-Phe-Tet s (derived from C534 ) .
  • D2704 and D2705 were each transformed sequentially with pD2634, pD2643 and pD2625 - by selection for Amp R , Tet R and Cam R , respectively, using conventional calcium shock to render the host competent for transformation.
  • These plasmids carry the genes for the key enzymes of tryptophan biosynthesis and were described hereinafccve.
  • One triple transformant in each case was used for nuclear magnetic resonance (NMR) analysis.
  • This culture was transferred to an NMR tube and used directly for N MR spectroscopy at 28 °C using a Varion Associates XL200 NMR spectrcmetry system. Aeration of the culture was achieved by rotating the tube and pumping air through the culture during the run. Spectra were acquired at 3-hour intervvls. Analysis of results
  • Table II summarizes the efficiency of conversion of glucose to tryptophan by the strains described immediately above.
  • Fran the intensity of the peaks of the NMR spectra corresponding to C6-glucose and C6-tryptophan, one can calculate the increase in tryptophan relative to the decrease in glucose (after making allowance for the molecular weights of the two compounds).
  • strains also carry the following markers: (argF-lac) U169, arcG FBR , ⁇ (trp-lac) W205, trpE fbr 31, tyrR366, tyrA4, tna2, bglR6, (lysC-pgi-malE) , trpR, (anthranilate-resistance).
  • the genotype of the host strain, D2618 is as follows: W3110 F-( argF-lac) U169, aroG PBR , ⁇ (trp-lac) W205, trpE FBR 31, tyrR366, tyrA4, tna2, bglR6, (lysC-pgi-malE) , tyrB507, zjb, trpR, (anthranilate-resistance).
  • D2715 is derived from D2618 by introducing deletions into the pheA gene and into the structural gene for serine deaminase.
  • the general method according to the invention comprises the steps of transforming an E . coli host deficient in tryptophanase with plasmid-borne genetic information to control tryptophan prcduction divided between at least two plaanids, growing the transformed host in an appropriate nutrient median for a period of time sufficient to produce tryptophan as exemplified above, and producing tryptophan by the transformed host.
  • Tryptophan from the culture broth may be removed by any conventional technique.
  • the tryptophan so obtained may be further refined or purified as desired.
  • the host in addition to being Tna-, will be deficient in the activity of phosphoglucose isomerase (pgi-).
  • the host in addition to or instead of being pgi-, may also have DAHP synthetase activity resistant to aromatic anirio acid inhibition, anthranilate synthetase activity resistant to tryptophan innibition, deficiencies in the activity of lac repressor, aromatic transaminase A, L-serine deaninase either singly or in any combinations thereof.
  • the inventor has also provided a method for increasing the production of tryptophan in a host of the genus Escherichia, particularly E. coli by transforming an E.coli host deficient in the enzyme tryptophanase with a plaanid carrying plaanid-borne genetic information to control tryptophan production, a portion of said information including lac operator/promoter control, growing the transformed host in an appropriate median as exemplified above and prcducing tryptophan by the transformed host.
  • the E. coli host will have the additional characteristics described above with respect to pgi-, DAHP synthetase, anthranilate synthesis, lac repressor activity, aromatic transaminase and L-serine deaminase.
  • the preferred E. coli host is transformed with plasmid-borne genetic information to control tryptophan production divided between at least two plaanids, a portion of the information to control tryptophan prcduction being under lac operator/promoter control.

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Microorganismes d'Escherichia coli véhiculant des informations génétiques portées par les plasmides et relatives à la production de L-tryptophane, et procédés permettant de produire ou d'accroître la production de L-tryptophane par fermentation.
EP19850904319 1985-08-15 1985-08-15 Microorganisme producteur de tryptophane. Withdrawn EP0232262A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1985/001542 WO1987001130A1 (fr) 1985-08-15 1985-08-15 Microorganisme producteur de tryptophane

Publications (2)

Publication Number Publication Date
EP0232262A1 true EP0232262A1 (fr) 1987-08-19
EP0232262A4 EP0232262A4 (fr) 1989-09-19

Family

ID=22188804

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19850904319 Withdrawn EP0232262A4 (fr) 1985-08-15 1985-08-15 Microorganisme producteur de tryptophane.

Country Status (2)

Country Link
EP (1) EP0232262A4 (fr)
WO (1) WO1987001130A1 (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047538A1 (fr) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Analogue de chaine gamma commune de recepteur de cytokine
WO2002016625A2 (fr) 2000-08-25 2002-02-28 Basf Plant Science Gmbh Polynucleotides vegetaux codant de nouvelles proteases prenyle
EP1683865A2 (fr) 2001-02-02 2006-07-26 Eli Lilly & Company Protéines de mammifères en particulier CD200
WO2007056352A2 (fr) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire
WO2007084631A2 (fr) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans un cancer du poumon non a petites cellules chez un etre humain
WO2007124464A2 (fr) 2006-04-20 2007-11-01 Becton, Dickinson And Company Protéines thermostables et procédés pour les préparer et les utiliser
WO2008105797A2 (fr) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucléotides codant pour de nouveaux variants du pcsk9
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
EP2025682A2 (fr) 1996-08-16 2009-02-18 Human Genome Sciences, Inc. Endoquine humaine alpha
WO2009041501A1 (fr) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. Facteur impliqué dans l'infection latente par le virus de l'herpès, et son utilisation
EP2055718A1 (fr) 2005-11-11 2009-05-06 Ludwig-Maximilians-Universität München Ciblage et suivi d'antigènes dans des cellules vivantes
EP2065396A1 (fr) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukine-19
EP2080766A1 (fr) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company Acides nucléiques et polypeptides apparentés à B7 utiles pour l'immunomodulation
WO2010093928A2 (fr) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Expression de la protéine mutante ros dans les cancers chez l'être humain
WO2010093993A2 (fr) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
EP2228389A2 (fr) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Anticorps contre facteur de croissance endothéliale vasculaire 2
EP2230307A1 (fr) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine Alpha
EP2264174A2 (fr) 1998-07-22 2010-12-22 SmithKline Beecham Limited Protéine semblable à la protéine spécifique des cellules neuroendocriniennes et ADNc codant
EP2287339A1 (fr) 2004-05-18 2011-02-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
EP2287310A1 (fr) 2004-07-22 2011-02-23 Five Prime Therapeutics, Inc. Compositions et procedes d'utilisation pour le facteur de stimulation de colonies de monocytes, de granulocytes et de cellules dendritiques dans le traitement de maladies
EP2290080A2 (fr) 2000-11-28 2011-03-02 Celltech R & D, Inc. Compositions et procédés de diagnostic et de traitement du psoriasis
EP2301969A1 (fr) 2005-05-06 2011-03-30 ZymoGenetics, L.L.C. Anticorps monoclonaux IL-31 et procédés d'utilisation
EP2332975A1 (fr) 1997-05-30 2011-06-15 Human Genome Sciences, Inc. Protéines humaines
EP2332961A2 (fr) 2001-10-11 2011-06-15 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
WO2012009631A1 (fr) 2010-07-15 2012-01-19 Synovex Corporation Anticorps humanisés ayant pour cible le domaine ec1 de la cadhérine 11 et compositions et méthodes associées
EP2431054A2 (fr) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Facteur delta de nécrose de tumeur humaine et epsilon
EP2471817A2 (fr) 2007-12-07 2012-07-04 ZymoGenetics, Inc. Molécules d'anticorps humanisés spécifiques pour l'IL-31
WO2013033680A1 (fr) 2011-09-02 2013-03-07 Lifenet Health Peptides bmp & procédés d'utilisation
EP2594586A1 (fr) 2006-09-01 2013-05-22 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
WO2013174003A1 (fr) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions et procédés associés à la prévention et au traitement d'une infection rabique
EP2685260A1 (fr) 2012-07-09 2014-01-15 Ludwig-Maximilians-Universität München Détection quantitative et directe de cibles dans des cellules vivantes
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
WO2016040488A2 (fr) 2014-09-10 2016-03-17 Georgetown University Compositions et procédés d'utilisation de l'il4i1 (interleukine-4 induced gene 1)
EP3023502A1 (fr) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions et procédés pour détecter des mutations egfr dans le cancer
WO2016081728A1 (fr) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Ostéocalcine comme traitement de fragilité associée au vieillissement
EP3031470A2 (fr) 2005-09-09 2016-06-15 The Johns Hopkins University Manipulation de cellules t régulatrices et fonction cc par ciblage de gènes de neuritine utilisant des anticorps, des agonistes et des antagonistes
EP3037544A1 (fr) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps
EP3072963A1 (fr) 2007-10-18 2016-09-28 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans l'épithélioma pulmonaire humain à grandes cellules
EP3181588A1 (fr) 2008-01-11 2017-06-21 Adheron Therapeutics, Inc. Antagonistes cadherin-11 et procédés de traitement de troubles inflammatoires des articulations
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
WO2019094595A2 (fr) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Méthodes et compositions pour la génération et l'utilisation d'anticorps tau phosphorylés spécifiques à une conformation humanisée
WO2019244107A1 (fr) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions comprenant des fragments de liaison à l'antigène cd3 et leurs utilisations
WO2020053808A1 (fr) 2018-09-12 2020-03-19 Georg Dewald Procédé de diagnostic de troubles vasorégulateurs
WO2022153194A1 (fr) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Conjugué anticorps-dérivé de pyrrolobenzodiazépine
WO2022153195A1 (fr) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Conjugué anticorps-médicament anti-dll3

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0746994B2 (ja) * 1984-10-04 1995-05-24 味の素株式会社 発酵法によるｌ−アミノ酸の製造法
WO1987002984A1 (fr) * 1985-11-12 1987-05-21 American Biogenetics Corporation Cassette biogenetique
JP2967996B2 (ja) * 1989-06-06 1999-10-25 協和醗酵工業株式会社 Ｌ―トリプトファンの製造法
DE4232468A1 (de) * 1992-09-28 1994-03-31 Consortium Elektrochem Ind Mikroorganismen für die Produktion von Tryptophan und Verfahren zu ihrer Herstellung
DE69637492T2 (de) 1995-05-05 2009-06-04 Genencor International, Inc., Palo Alto Anwendung von Glukosetransportmutanten zur Herstellung von Verbindungen des aromatischen Syntheseweges
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US5939295A (en) * 1996-03-29 1999-08-17 Archer Daniels Midland Company Production of tryptophan by microorganisms
EP1141237B1 (fr) 1998-12-31 2005-11-02 The General Hospital Corporation Recepteur pth et test de criblage l'utilisant
EP1439854B1 (fr) 2001-07-23 2016-12-14 The General Hospital Corporation Analogues d'hormone parathyroide (pth) a contrainte conformationnelle
US8372989B2 (en) 2002-04-23 2013-02-12 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of monatin and its precursors
AU2003263097A1 (en) 2002-04-23 2003-11-10 Cargill, Incorporated Polypeptides and biosynthetic pathways
US7572607B2 (en) 2002-04-23 2009-08-11 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of monatin and its precursors
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US20050079617A1 (en) 2003-10-03 2005-04-14 Cervin Marguerite A. Glucose transport mutants for production of biomaterial
WO2004033421A2 (fr) 2002-10-04 2004-04-22 Genencor International, Inc. Production amelioree de souches bacteriennes
AU2004263855A1 (en) 2003-08-01 2005-02-17 Cargill, Incorporated Monatin tabletop sweetener compositions and methods of making same
RU2006117353A (ru) 2003-10-21 2007-12-27 Карджилл, Инкорпорейтед (Us) Получение монатина и предшественников монатина
US8158389B2 (en) 2005-04-20 2012-04-17 Cargill, Incorporated Products and methods for in vivo secretion of monatin
RU2007142666A (ru) 2005-04-20 2009-05-27 Карджилл, Инкорпорейтед (Us) Продукты и способы для секреции монатина in vivo
DE102005018835A1 (de) 2005-04-22 2006-11-02 Degussa Ag Verfahren zur Herstellung von L-Aminosäuren unter Verwendung verbesserter Stämme der Familie Enterobacteriaceae
DE102005019040A1 (de) 2005-04-23 2006-10-26 Degussa Ag Verfahren zur Herstellung von L-Aminosäuren unter Verwendung verbesserter Stämme der Familie Enterobacteriaceae
US7582455B2 (en) 2005-04-26 2009-09-01 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
US8076108B2 (en) 2005-04-26 2011-12-13 Cargill, Incorporated Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
KR100792095B1 (ko) 2006-12-29 2008-01-04 씨제이 주식회사 Ｌ-페닐알라닌 생산능을 갖는 대장균 변이주로부터유전자조작된 ｌ-트립토판 생산능을 갖는 재조합 대장균균주 및 이를 이용한 트립토판 제조방법
DE102007051024A1 (de) 2007-03-05 2008-09-11 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von Stämmen der Familie Enterobacteriaceae
EP1975241A1 (fr) 2007-03-29 2008-10-01 Evonik Degussa GmbH Procédé de fabrication d'aminoacides L en utilisant des troncs améliorés de la famille des enterobacteriaceae
CA3017668C (fr) 2007-08-01 2021-11-09 The General Hospital Corporation Procedes de criblage a recepteurs couples a la proteine g et compositions apparentees
DE102007044134A1 (de) 2007-09-15 2009-03-19 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
DE102007052270A1 (de) 2007-11-02 2009-05-07 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
EP2060636A1 (fr) 2007-11-14 2009-05-20 Evonik Degussa GmbH Procédé de fabrication d'acides aminés L en utilisant des souches de la famille des Enterobacteriaceae améliorées
EP2098597A1 (fr) 2008-03-04 2009-09-09 Evonik Degussa GmbH Procédé de fabrication d'aminoacides L en utilisant des troncs améliorés de la famille des enterobacteriaceae
DE102008002309A1 (de) 2008-06-09 2009-12-10 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
DE102008040352A1 (de) 2008-07-11 2010-01-14 Evonik Degussa Gmbh Verfahren zur Herstellung von L-Tryptophan unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
DE102008044768A1 (de) 2008-08-28 2010-03-04 Evonik Degussa Gmbh Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
PL2608805T3 (pl) 2010-08-23 2017-12-29 Wyeth Llc Trwałe preparaty antygenów rLP2086 Neisseria meningitidis
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
KR101532129B1 (ko) * 2012-01-10 2015-06-29 씨제이제일제당 (주) L-트립토판 생산능이 강화된 에스케리키아속 미생물 및 이를 이용하여 l-트립토판을 생산하는 방법
EP2628792A1 (fr) 2012-02-17 2013-08-21 Evonik Industries AG Cellule dotée d'une activité ppGppase moindre
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2762571A1 (fr) 2013-01-30 2014-08-06 Evonik Industries AG Microorganisme et procédé de fabrication par fermentation d'acides aminés
WO2014136064A2 (fr) 2013-03-08 2014-09-12 Pfizer Inc. Polypeptides immunogènes de fusion
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3270959A1 (fr) 2015-02-19 2018-01-24 Pfizer Inc Compositions de neisseria meningitidis et méthodes associées
EP3577130A2 (fr) 2017-01-31 2019-12-11 Pfizer Inc Compositions de neisseria meningitidis et méthodes associées
EP3385275B1 (fr) 2017-04-07 2019-10-23 Evonik Degussa GmbH Procédé de fabrication d'aminoacides l aromatiques à l'aide de troncs améliorés de la famille des enterobacteriaceae
US11053526B2 (en) 2018-08-09 2021-07-06 Evonik Operations Gmbh Process for preparing L amino acids using improved strains of the enterobacteriaceae family
WO2020208191A1 (fr) * 2019-04-10 2020-10-15 Technische Universität Hamburg Nouvelle synthase dhap

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124048A2 (fr) * 1983-04-23 1984-11-07 Ajinomoto Co., Inc. Procédé de production de L-tryptophane par fermentation
EP0145156A1 (fr) * 1983-10-07 1985-06-19 Biotechnica International, Inc. Vecteurs d'expression, cellules hôtes contenant de tels vecteurs et méthodes pour la production des composés désirés utilisant de telles cellules
EP0149539A2 (fr) * 1984-01-13 1985-07-24 Stauffer Chemical Company Souches mutantes à activité de L-sérine désaminase déficiente et leur utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371614A (en) * 1980-08-22 1983-02-01 Ajinomoto Co., Inc. E.Coli bacteria carrying recombinant plasmids and their use in the fermentative production of L-tryptophan
EP0077196A3 (fr) * 1981-10-09 1984-06-06 Genex Corporation Microorganismes produisant des acides aminés aromatiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124048A2 (fr) * 1983-04-23 1984-11-07 Ajinomoto Co., Inc. Procédé de production de L-tryptophane par fermentation
EP0145156A1 (fr) * 1983-10-07 1985-06-19 Biotechnica International, Inc. Vecteurs d'expression, cellules hôtes contenant de tels vecteurs et méthodes pour la production des composés désirés utilisant de telles cellules
EP0149539A2 (fr) * 1984-01-13 1985-07-24 Stauffer Chemical Company Souches mutantes à activité de L-sérine désaminase déficiente et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8701130A1 *

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025682A2 (fr) 1996-08-16 2009-02-18 Human Genome Sciences, Inc. Endoquine humaine alpha
EP2065396A1 (fr) 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukine-19
EP2230307A1 (fr) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine Alpha
EP2332975A1 (fr) 1997-05-30 2011-06-15 Human Genome Sciences, Inc. Protéines humaines
WO1999047538A1 (fr) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Analogue de chaine gamma commune de recepteur de cytokine
EP1982990A1 (fr) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Récepteur de cytokine et chaîne de gamma commune similaire
EP2264174A2 (fr) 1998-07-22 2010-12-22 SmithKline Beecham Limited Protéine semblable à la protéine spécifique des cellules neuroendocriniennes et ADNc codant
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
EP2431054A2 (fr) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Facteur delta de nécrose de tumeur humaine et epsilon
WO2002016625A2 (fr) 2000-08-25 2002-02-28 Basf Plant Science Gmbh Polynucleotides vegetaux codant de nouvelles proteases prenyle
EP2290080A2 (fr) 2000-11-28 2011-03-02 Celltech R & D, Inc. Compositions et procédés de diagnostic et de traitement du psoriasis
EP1683865A2 (fr) 2001-02-02 2006-07-26 Eli Lilly & Company Protéines de mammifères en particulier CD200
EP2228389A2 (fr) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Anticorps contre facteur de croissance endothéliale vasculaire 2
EP2080766A1 (fr) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company Acides nucléiques et polypeptides apparentés à B7 utiles pour l'immunomodulation
EP2371836A1 (fr) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2366707A1 (fr) 2001-10-11 2011-09-21 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2371838A1 (fr) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2371837A1 (fr) 2001-10-11 2011-10-05 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2351767A2 (fr) 2001-10-11 2011-08-03 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2348036A2 (fr) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2348035A2 (fr) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2348034A2 (fr) 2001-10-11 2011-07-27 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2343308A2 (fr) 2001-10-11 2011-07-13 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP3199539A1 (fr) 2001-10-11 2017-08-02 Wyeth Holdings LLC Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2332961A2 (fr) 2001-10-11 2011-06-15 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2341062A2 (fr) 2001-10-11 2011-07-06 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP2341063A2 (fr) 2001-10-11 2011-07-06 Wyeth Holdings Corporation Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
EP3056571A1 (fr) 2004-05-18 2016-08-17 Georg Dewald Procédés et kits pour détecter un oedème de quincke héréditaire de type iii
EP2287339A1 (fr) 2004-05-18 2011-02-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
EP2287310A1 (fr) 2004-07-22 2011-02-23 Five Prime Therapeutics, Inc. Compositions et procedes d'utilisation pour le facteur de stimulation de colonies de monocytes, de granulocytes et de cellules dendritiques dans le traitement de maladies
EP2479277A2 (fr) 2004-07-22 2012-07-25 Five Prime Therapeutics, Inc. Compositions et procédés pour l'utilisation de MGD-CSF dans le traitement de maladies
EP2301969A1 (fr) 2005-05-06 2011-03-30 ZymoGenetics, L.L.C. Anticorps monoclonaux IL-31 et procédés d'utilisation
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
EP3031470A2 (fr) 2005-09-09 2016-06-15 The Johns Hopkins University Manipulation de cellules t régulatrices et fonction cc par ciblage de gènes de neuritine utilisant des anticorps, des agonistes et des antagonistes
EP3037544A1 (fr) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps
WO2007056352A2 (fr) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire
EP2055718A1 (fr) 2005-11-11 2009-05-06 Ludwig-Maximilians-Universität München Ciblage et suivi d'antigènes dans des cellules vivantes
EP2671954A2 (fr) 2006-01-20 2013-12-11 Cell Signaling Technology, Inc. Translocation et kinase ROS mutante dans un cancer du poumon non à petites cellules chez un être humain
WO2007084631A2 (fr) 2006-01-20 2007-07-26 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans un cancer du poumon non a petites cellules chez un etre humain
EP3936621A1 (fr) 2006-01-20 2022-01-12 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans un carcinome pulmonaire non à petites cellules humaines
EP3360965A1 (fr) 2006-01-20 2018-08-15 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans un carcinome humain pulmonaire non à petites cellules
WO2007124464A2 (fr) 2006-04-20 2007-11-01 Becton, Dickinson And Company Protéines thermostables et procédés pour les préparer et les utiliser
EP2671946A1 (fr) 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucléotides codant de nouveaux variants de PCSK9
EP2639301A2 (fr) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynucléotides codant de nouveaux variants de PCSK9
WO2008105797A2 (fr) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucléotides codant pour de nouveaux variants du pcsk9
EP2594586A1 (fr) 2006-09-01 2013-05-22 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
EP2759549A2 (fr) 2006-09-01 2014-07-30 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
EP2987859A1 (fr) 2007-09-27 2016-02-24 Japan Tobacco Inc Facteur impliqué dans une infection latente par un herpès virus et son utilisation
WO2009041501A1 (fr) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. Facteur impliqué dans l'infection latente par le virus de l'herpès, et son utilisation
EP3072963A1 (fr) 2007-10-18 2016-09-28 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans l'épithélioma pulmonaire humain à grandes cellules
EP3741851A1 (fr) 2007-10-18 2020-11-25 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans un carcinome pulmonaire non à petites cellules humaines
EP2471817A2 (fr) 2007-12-07 2012-07-04 ZymoGenetics, Inc. Molécules d'anticorps humanisés spécifiques pour l'IL-31
EP2796466A2 (fr) 2007-12-07 2014-10-29 ZymoGenetics, Inc. Molécules d'anticorps humanisés spécifiques pour l'IL-31
EP3181588A1 (fr) 2008-01-11 2017-06-21 Adheron Therapeutics, Inc. Antagonistes cadherin-11 et procédés de traitement de troubles inflammatoires des articulations
EP3023502A1 (fr) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions et procédés pour détecter des mutations egfr dans le cancer
EP3266795A1 (fr) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Méthode de détection d'un polynucléotide codant pour une fusion fig-ros
EP2881402A1 (fr) 2009-02-12 2015-06-10 Cell Signaling Technology, Inc. Expression de la protéine mutante ROS dans les cancers du foie chez l'être humain
WO2010093993A2 (fr) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
WO2010093928A2 (fr) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Expression de la protéine mutante ros dans les cancers chez l'être humain
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
WO2012009631A1 (fr) 2010-07-15 2012-01-19 Synovex Corporation Anticorps humanisés ayant pour cible le domaine ec1 de la cadhérine 11 et compositions et méthodes associées
EP3345925A2 (fr) 2010-07-15 2018-07-11 Adheron Therapeutics, Inc. Anticorps humanisés ciblant le domaine ec1 cadhérine-11 et compositions et procédés associés
WO2013033680A1 (fr) 2011-09-02 2013-03-07 Lifenet Health Peptides bmp & procédés d'utilisation
US9290564B2 (en) 2012-05-24 2016-03-22 Mountgate Group Limited Compositions and methods related to the prevention and treatment of rabies infection
EP3508497A1 (fr) 2012-05-24 2019-07-10 Mountgate Group Limited Compositions et procédés associés à la prévention et au traitement d'une infection rabique
WO2013174003A1 (fr) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions et procédés associés à la prévention et au traitement d'une infection rabique
EP2685260A1 (fr) 2012-07-09 2014-01-15 Ludwig-Maximilians-Universität München Détection quantitative et directe de cibles dans des cellules vivantes
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
WO2016040488A2 (fr) 2014-09-10 2016-03-17 Georgetown University Compositions et procédés d'utilisation de l'il4i1 (interleukine-4 induced gene 1)
WO2016081728A1 (fr) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Ostéocalcine comme traitement de fragilité associée au vieillissement
WO2019094595A2 (fr) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Méthodes et compositions pour la génération et l'utilisation d'anticorps tau phosphorylés spécifiques à une conformation humanisée
WO2019244107A1 (fr) 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions comprenant des fragments de liaison à l'antigène cd3 et leurs utilisations
WO2020053808A1 (fr) 2018-09-12 2020-03-19 Georg Dewald Procédé de diagnostic de troubles vasorégulateurs
WO2022153194A1 (fr) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Conjugué anticorps-dérivé de pyrrolobenzodiazépine
WO2022153195A1 (fr) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Conjugué anticorps-médicament anti-dll3

Also Published As

Publication number Publication date
WO1987001130A1 (fr) 1987-02-26
EP0232262A4 (fr) 1989-09-19

Similar Documents

Publication Publication Date Title
EP0232262A1 (fr) Microorganisme producteur de tryptophane
US5658766A (en) Strains of Escherichia coli which produce isoleucine or valine and a method for their production
US4371614A (en) E.Coli bacteria carrying recombinant plasmids and their use in the fermentative production of L-tryptophan
EP0763127B1 (fr) Deblocage de la voie commune de synthese des acides amines aromatiques
US4407952A (en) Method for producing L-phenylalanine by fermentation
US4346170A (en) Method for producing L-lysine by fermentation
US6962794B2 (en) Application of glucose transport mutants for production of aromatic pathway compounds
EP0030727B1 (fr) Procédé de production de L-valine par fermentation et procédé de production d'un microorganisme du genre escherichia
US4430430A (en) Method for producing L-arginine by fermentation
EP0789073A2 (fr) Préparation de tryptophane en utilisant la bacterie Escherichia coli
EP0136359A1 (fr) Procede de preparation de l acide amine l-histidine
EP1149911A2 (fr) Souches d'Escherichia produisant des acides aminés et procédé de production d'acide aminé
GB2055805A (en) Preparation of l-histidine by fermentation
EP1322765A1 (fr) Souches d' escherichia coli / sur-produisant de la l-threonine et procede de production de l-threonine par fermentation
AU2001296415A1 (en) Escherichia coli strains which over-produce L-threonine and processes for the production of L-threonine by fermentation
JP2003506030A (ja) アミノ酸産生の代謝工学
US5034318A (en) Method for producing L-tryptophan by fermentation
US5426050A (en) Plasmid vectors for expression of genes in coryneform bacteria
KR900004424B1 (ko) 아미노산의 제조방법
US4393135A (en) Method for producing L-glutamic acid by fermentation
EP0183006B1 (fr) Molécule d'ADN recombinant, bactéries corynéformes comprenant l'ADN recombinant et procédé de préparation d'un acide aminé aromatique en utilisant celles-ci
EP0519113A1 (fr) Souches de bactérie avec une production élévée en acide aminé et procédé de preparation de ces souches
US20080241898A1 (en) Application of Glucose Transport Mutants For Production Of Aromatic Pathway Compounds
EP0178744A2 (fr) Vecteur navette
EP0293207A2 (fr) Escherichia coli contenant une plasmide recombinante pour la production de tryptophane

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19870806

A4 Supplementary search report drawn up and despatched

Effective date: 19890919

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19900716

R18W Application withdrawn (corrected)

Effective date: 19900716

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MASCARENHAS, DESMOND